HRP20260618T1 - Gdnf fuzijski polipeptidi i postupci njihove primjene - Google Patents
Gdnf fuzijski polipeptidi i postupci njihove primjeneInfo
- Publication number
- HRP20260618T1 HRP20260618T1 HRP20260618TT HRP20260618T HRP20260618T1 HR P20260618 T1 HRP20260618 T1 HR P20260618T1 HR P20260618T T HRP20260618T T HR P20260618TT HR P20260618 T HRP20260618 T HR P20260618T HR P20260618 T1 HRP20260618 T1 HR P20260618T1
- Authority
- HR
- Croatia
- Prior art keywords
- methods
- fusion polypeptides
- gdnf fusion
- gdnf
- polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420480P | 2016-11-10 | 2016-11-10 | |
| EP17870175.1A EP3538560B1 (en) | 2016-11-10 | 2017-11-09 | Gdnf fusion polypeptides and methods of use thereof |
| PCT/US2017/060953 WO2018089702A1 (en) | 2016-11-10 | 2017-11-09 | Gdnf fusion polypeptides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20260618T1 true HRP20260618T1 (hr) | 2026-07-17 |
Family
ID=62110755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20260618TT HRP20260618T1 (hr) | 2016-11-10 | 2017-11-09 | Gdnf fuzijski polipeptidi i postupci njihove primjene |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11912750B2 (enExample) |
| EP (2) | EP3538560B1 (enExample) |
| JP (1) | JP2019535267A (enExample) |
| CN (1) | CN110461880A (enExample) |
| AU (2) | AU2017357931B2 (enExample) |
| CA (1) | CA3043179A1 (enExample) |
| DK (1) | DK3538560T3 (enExample) |
| ES (1) | ES3071925T3 (enExample) |
| FI (1) | FI3538560T3 (enExample) |
| HR (1) | HRP20260618T1 (enExample) |
| LT (1) | LT3538560T (enExample) |
| PT (1) | PT3538560T (enExample) |
| WO (1) | WO2018089702A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11912750B2 (en) | 2016-11-10 | 2024-02-27 | Keros Therapeutics, Inc. | GDNF fusion polypeptides and methods of use thereof |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| BR112021024636A2 (pt) * | 2019-06-10 | 2022-01-18 | Infectious Disease Res Inst | Métodos e composições de replicons de astrovírus |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| WO2021257480A2 (en) * | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
| CN113046381A (zh) * | 2021-04-12 | 2021-06-29 | 南华大学 | 用于分离生物体内特异性蛋白-dna复合体的方法、融合蛋白及其制备方法 |
| CN115927288A (zh) * | 2022-07-28 | 2023-04-07 | 南京林业大学 | 一种固定化脂肪tll酶及固体结合肽在其固定化中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| GB8909916D0 (en) * | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| US20040175795A1 (en) | 1991-09-20 | 2004-09-09 | Amgen Inc. | Glial derived neurotrophic factor |
| WO1993006116A1 (en) | 1991-09-20 | 1993-04-01 | Syntex-Synergen Neuroscience Joint Venture | Glial derived neurotrophic factor |
| US5733875A (en) | 1994-11-15 | 1998-03-31 | Amgen Inc. | Methods of using GDNF as a neuroprotective agent |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO1996033731A1 (en) | 1995-04-26 | 1996-10-31 | Regeneron Pharmaceuticals, Inc. | Methods of using neurotrophic factors to enhance neuronal grafts |
| US6184200B1 (en) | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
| US5731284A (en) | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
| US5641750A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5641749A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
| AU1121997A (en) | 1995-11-29 | 1997-06-19 | Amgen, Inc. | Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product |
| US5837681A (en) | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5929041A (en) | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US6455277B1 (en) | 1996-04-22 | 2002-09-24 | Amgen Inc. | Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides |
| US7138251B1 (en) | 1996-04-22 | 2006-11-21 | Amgen Inc. | Polynucleotides encoding a neurotrophic factor receptor |
| JP2002505576A (ja) | 1997-05-30 | 2002-02-19 | アムジエン・インコーポレーテツド | 神経栄養因子レセプター |
| WO2000034475A2 (en) | 1998-12-09 | 2000-06-15 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
| US7608681B2 (en) * | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2003256613A1 (en) | 2002-07-19 | 2004-02-09 | Amgen Inc. | Protein conjugates with a water-soluble biocompatible, biogradable polymer |
| US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
| US8921528B2 (en) * | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AU2007285763B2 (en) * | 2006-08-18 | 2011-12-15 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| CN101687933B (zh) * | 2007-05-30 | 2015-11-25 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| EP2152751A1 (en) * | 2007-05-31 | 2010-02-17 | Genmab A/S | Fusion or linked proteins with extended half life |
| WO2009070597A2 (en) * | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CN103819564A (zh) * | 2009-06-11 | 2014-05-28 | 安吉奥开米公司 | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| WO2015073727A1 (en) * | 2013-11-13 | 2015-05-21 | Aequus Biopharma, Inc. | Engineered glycoproteins and uses thereof |
| AU2015231170B2 (en) * | 2014-03-20 | 2019-10-03 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
| US11912750B2 (en) | 2016-11-10 | 2024-02-27 | Keros Therapeutics, Inc. | GDNF fusion polypeptides and methods of use thereof |
-
2017
- 2017-11-09 US US16/348,982 patent/US11912750B2/en active Active
- 2017-11-09 FI FIEP17870175.1T patent/FI3538560T3/fi active
- 2017-11-09 HR HRP20260618TT patent/HRP20260618T1/hr unknown
- 2017-11-09 DK DK17870175.1T patent/DK3538560T3/da active
- 2017-11-09 AU AU2017357931A patent/AU2017357931B2/en active Active
- 2017-11-09 JP JP2019525814A patent/JP2019535267A/ja active Pending
- 2017-11-09 EP EP17870175.1A patent/EP3538560B1/en active Active
- 2017-11-09 ES ES17870175T patent/ES3071925T3/es active Active
- 2017-11-09 EP EP26170451.4A patent/EP4782462A2/en active Pending
- 2017-11-09 WO PCT/US2017/060953 patent/WO2018089702A1/en not_active Ceased
- 2017-11-09 CA CA3043179A patent/CA3043179A1/en active Pending
- 2017-11-09 PT PT178701751T patent/PT3538560T/pt unknown
- 2017-11-09 CN CN201780082828.8A patent/CN110461880A/zh active Pending
- 2017-11-09 LT LTEPPCT/US2017/060953T patent/LT3538560T/lt unknown
-
2024
- 2024-02-16 US US18/443,769 patent/US12404313B2/en active Active
-
2025
- 2025-03-04 AU AU2025201554A patent/AU2025201554A1/en active Pending
- 2025-08-01 US US19/287,981 patent/US20260022150A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110461880A (zh) | 2019-11-15 |
| LT3538560T (lt) | 2026-07-10 |
| EP3538560B1 (en) | 2026-04-08 |
| DK3538560T3 (da) | 2026-07-13 |
| US20190284251A1 (en) | 2019-09-19 |
| PT3538560T (pt) | 2026-06-15 |
| NZ754163A (en) | 2026-01-30 |
| US20260022150A1 (en) | 2026-01-22 |
| FI3538560T3 (fi) | 2026-07-03 |
| WO2018089702A1 (en) | 2018-05-17 |
| EP3538560A1 (en) | 2019-09-18 |
| US12404313B2 (en) | 2025-09-02 |
| US20240209048A1 (en) | 2024-06-27 |
| JP2019535267A (ja) | 2019-12-12 |
| US11912750B2 (en) | 2024-02-27 |
| ES3071925T3 (en) | 2026-06-26 |
| AU2025201554A1 (en) | 2025-03-27 |
| AU2017357931A1 (en) | 2019-06-20 |
| CA3043179A1 (en) | 2018-05-17 |
| EP4782462A2 (en) | 2026-07-29 |
| EP3538560A4 (en) | 2020-06-17 |
| AU2017357931B2 (en) | 2024-12-05 |